← Back to scoreboard
HealthcareMRK
Merck & Co
2026 AI narrative defined by Keytruda 2028 patent cliff ($29.5B, 56% of revenue). Mayo Clinic AI partnership and internal GenAI cutting study reports from 3 weeks to 3-4 days.
AI Impact Score
5.8/10
↔ Neutral
Scoring Breakdown
Sector Base
7
AI Revenue Exposure
5
Moat Durability
7
Disruption Risk (lower=better)
6
AI Adoption Maturity
7
Scenarios
Bull Case
$70B+ pipeline revenue target backed by 20 launches and 80 readouts. AI accelerating clinical execution compounds across all readouts.
Bear Case
Keytruda cliff is structural — must replace revenue equivalent of AbbVie's entire immunology franchise. AI cannot bridge 2028 cliff regardless of investment.
Key Factors to Watch
- ●Mayo Clinic AI partnership (Feb 2026) integrates clinical + genomic data with virtual cell models
- ●GenAI cuts clinical study report time from 3 weeks to 3-4 days
- ●Keytruda 2028 cliff: 56% revenue at risk — AI investment is existential response
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-03-08 | 5.8 | Neutral | Score 6.0→5.8 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 6.0 | Positive | Score 6.4->6.0 (are 7->5). External research cross-ref: AI primarily R&D tool (GPTeal 67% workforce, KERMT model, Tempus/Mayo partnerships) but revenue comes from Keytruda $31.7B (49% of total) |
| 2026-03-08 | 6.4 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-03-24
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.